Heberferon an alternative treatment in basal cell carcinomas in the facial region
Keywords:
CARCINOMA, BASAL CELL, SURGERY, INJURY.Abstract
Introduction: The etiopathogeneses of this type of tumor is related to age, genetic, viral and environmental factors (ultraviolet radiation). It initially presents as a small, slow-growing tumor, as an ulcerated lesion, with telangiectasias and a rounded border, and its signs may vary according to the clinical subtype.
Objective: to clinic-epidemiologically characterize patients over 20 years of age with basal cell carcinoma in the facial region treated with HeberFERON®.
Methods: a descriptive retrospective cross-sectional study was conducted in patients over 20 years of age with basal cell carcinoma (BCC) in the facial region of the General Teaching Hospital "Dr. Ernesto Guevara de la Serna", in the period 2020-2021. The universe consisted of 47 patients with basal cell carcinoma and with confirmatory biopsy of the lesion. The sample was represented by 33 patients who met the inclusion criteria, obtained by non-probabilistic purposive sampling.
Results: The male sex predominated with 66,7 %, the 76-85 age group was the most representative with 45,5 %. The nose was the anatomical site with the highest incidence. Fever and chills were the most frequent adverse reactions. Fainting was the main symptom and a complete response to treatment was observed in most of the study sample.
Conclusions: HeberFERON® enables a higher success rate in the treatment of multiple carcinomatosis and extensive lesions, as it is prescribed as an essential complement to the surgical procedure.
Downloads
References
1. Instituto Nacional del Cáncer. Cáncer de piel no melanoma [Internet]. NHI; 2022 [Citado 20/07/2022]. Disponible en: https://www.cancer.gov/espanol/publicaciones/diccionarios/diccionario-cancer/def/cancer-de-piel-no-melanoma
2. Cerón D, Ayon A. Prevalencia de cáncer de piel en pacientes de 18 a 50 años en el Hospital Teodoro Maldonado Carbó durante el período 2014 -2019. Rev. Oncología. Ecu [Internet]. 2020 [Citado 20/07/2022]; 30(1): 82-90. Disponible en: https://doi.org/10.33821/474
3. Massó DG, Oduardo EC, Soria LA. Presentación clínica atípica del carcinoma epidermoide cutáneo. Revista Cubana de Medicina Militar [Internet]. 2016 Apr [cited 14/01/2019]; 45(2): 215-220. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572016000200010
4. Roque-Pérez L, González-Escudero M. HeberFERON: solución efectiva para el carcinoma basocelular. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta [Internet]. 2019 [Citado 20/07/2022]; 44(3). Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/1713
5. Negrín-Caceres Y, Cabrera-Romero AC, Cárdenas-Monzón L, Ferrer-Pérez A, Batista-Hernández NE. Tratamiento del carcinoma basocelular periocular con una combinación sinérgica de interferones alpha-2b y gamma. Rev. Mex. Oftalmol [Internet]. 2018 [Citado 20/07/2022]; 92(3). Disponible en: https://www.researchgate.net/publication/325077065_Tratamiento_del_carcinoma_basocelular_periocular_con_una_combinacion_sinergica_de_interferones_alpha-2b_y_gamma
6. Rojas Rondón I, Duncan Roberts Y, Gómez Cabrera CG, Ramírez García
LK, Vigoa Aranguren L, HernándezRodríguez R, et al. Administraciónde HeberFERON en el carcinomabasocelular palpebral a propósito de2 casos. Bionatura [Internet]. 2016 [citado el 20/02/2018]; 1(2): 71-74. Disponible en: https://www.revistabionatura.com/heberferon.html
7. Centro para el Control Estatal de Medicamentos, Equipos y DispositivosMédicos. Resumen de las características del producto: HeberFERON® [Internet]. La Habana: Ministerio deSalud Pública; 2017 [citado el 12/02/2018]. Disponible en: https://www.cecmed.cu/sites/default/fles/adjuntos/rcp/biologicos/rcp_heberferon_0.pdf
8. Bello-Álvarez C, Vázquez-Blomquist D, Miranda J, García Y, Novoa LI,
Palenzuela D, et al. Regulation by IFN-α/IFN-γ co-formulation (HerberPAG®) of genes involved in interferon-STAT-pathways andapoptosis in U87MG. Curr Top Med Chem [Internet]. 2014 [citado el 12/2/2018]; 14(3): 351-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24304312
9. Pérez Bernal L, Suárez Alfonso OE, González González M, Rodríguez Maqueira A. Epidemiología de laslesiones malignas epiteliales. Rev. Universidad Médica Pinareña [Internet]. 2015 [citado 10/12/2018]; 11(2): 15-23. Disponible en: https://revgaleno.sld.cu/index.php/ump/article/view/114/html
10. Aroche Domínguez ME, Hernández Del Pino S, Abijana Damián G, Alina Balón Ferrer A, Bordelois Abdo JA. Comportamiento histológico de cáncer de piel. Estudio de tres años en la provincia de Guantánamo. Rev Inf Cient [Internet]. 2012 [citado 06/03/2015]; 75(3). Disponible en: https://revinfcientifica.sld.cu/index.php/ric/article/view/836
11. Guevara Hornia A. Enfermedades malignas y premalignas de piel en el paciente geriátrico. Sancti Spíritus. Año 2010. Gaceta Médica Espirituana [Internet]. 2012 [citado 06/03/2015]; 14(3): 6. Disponible en: https://revgmespirituana.sld.cu/index.php/gme/article/view/195/151
12. Acosta Medina DL, Bravo Hernández A, Ruíz Acosta D, Acosta Medina GM. Comportamiento del cáncer de piel en Güines y San José de las Lajas. Medimay [Internet]. 2014 [citado 06/03/2015]; 20(1): 44-53. Disponible en: http://revcmhabana.sld.cu/index.php/rcmh/article/view/179/html
13. Albornoz López del Castillo C, Zequeira Peña JL. Caracterización clínico-histopatológica del liquen plano bucal en las consultas de diagnóstico precoz del cáncer bucal. AMC [Internet]. 2012 Ago [citado 06/03/2020]; 16(4): 419-430. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552012000400007&lng=es.
14. López Pupo N, Manganelly Fonseca Y, Tablada Robinet ME, Jacas Portuondo AL, Girón Maturell Y. Utilidad del HeberFERON® en pacientes con carcinoma basocelular. MEDISAN [Internet]. 2021 [citado 06/03/2020]; 25(6): 1297- 1308. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192021000601297.
15. Russo T, Piccolo V, Lallas A, Jacomel J, Moscarella E, Alfano R, et al. Dermoscopyof Malignant Skin Tumours: What’s New? Dermatology [Internet]. 2017 [citado 06/03/2020]; 233(1): 64-73. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28486238.
16. Ferrá-Torres TM, Sánchez-Rodríguez ES, Ballester-Caballero Y, Sallary-Gutiérrez K. Caracterización de pacientes con carcinoma basocelular tratados con HeberFERON. AMC [Internet]. Abr 2020 [citado 06/03/2020]; 24(2): e7136. Disponible en: http://scielo.sld.cu/pdf/amc/v24n2/1025-0255-amc-24-02-e7136.pdf.
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
